ESR1 and prostate adenocarcinoma: After 24 h of incubation, the same dose of quercetin differentially reduced cell viability by between 20% and 47% in nine different cancer cell lines (colon carcinoma CT-26 cells, prostate adenocarcinoma LNCaP cells, human prostate PC3 cells, pheocromocytoma PC12 cells, estrogen receptor-positive breast cancer MCF-7 cells, acute lymphoblastic leukemia MOLT-4 T-cells, human myeloma U266B1 cells, human lymphoid Raji cells, and ovarian cancer CHO cells) [26].